TikTok has reached a deal that will allow it to keep operating in the United States, with a majority American-owned joint venture, but the terms could change the algorithm for users in the U.S. The ...
Meta has now rolled out the "Build Your 2026 Algorithm" feature for Instagram Reels to allow users use it to personalize their feeds. Instagram Reels 'Build Your 2026 Algorithm' Now Live After a test ...
Dec 8 (Reuters) - Recursion Pharma (RXRX.O), opens new tab, which uses artificial intelligence to discover new drug candidates, said on Monday its experimental oral drug helped reduce abnormal growths ...
Andrew Joseph covers health, medicine, and the biopharma industry in Europe. You can reach Andrew on Signal at drewqjoseph.71. LONDON — In the year-plus since Najat Khan joined the AI-focused drug ...
After a challenging 12 years trying to use AI to create new medicines, cofounder Chris Gibson stepped down as CEO last week. Can R&D chief and new CEO Najat Khan turn it around? In 2014, Recursion ...
Management reaffirmed guidance for 2025 on an expense base of less than $450 million, "excluding all of the partnership inflows." For 2026, guidance was also reaffirmed at less than $390 million.
On October 25-26, Vietnam collaborated with the United Nations Office on Drugs and Crime (UNODC) to host the signing ceremony of the Hanoi Convention, formally known as the U.N. Convention Against ...
The original version of this story appeared in Quanta Magazine. If you want to solve a tricky problem, it often helps to get organized. You might, for example, break the problem into pieces and tackle ...
Recursion Pharmaceuticals Inc. (NASDAQ:RXRX) stock is surging on Wednesday, without any news to justify the movement. Session volume stands at 69.3 million versus the average volume of 26.9 million, ...
HANOI, Oct 7 (Reuters) - Torrential rains triggered by Typhoon Matmo flooded parts of Hanoi on Tuesday, the latest in a series of deluges that have inundated the Vietnamese capital over the past month ...
Recursion Pharmaceuticals uses AI to expedite the laborious process of developing drugs. The company could benefit from industry-wide regulatory changes as well as its own clinical progress. However, ...